MELTEMI and COLUMBA: 5-Year Comparative Safety Analysis of Benralizumab and Mepolizumab
Key words
Eosinophils
asthma
patient safety
respiratory infections
adverse events
biologic agents
injection site adverse reaction
Abbreviations usedHRQoL
Health-related quality of life
ICS
Inhaled corticosteroid[s]
LABA
Long-acting ß2-agonist
OCS
Oral corticosteroid[s]
RTI
Respiratory tract infection
SEA
Severe eosinophilic asthma
© 2024 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
留言 (0)